Effects of anti-miR-17 or anti-miR-19 LNA antagomirs on donor T-cell alloresponse and GVHD. BALB/c mice were lethally irradiated and transplanted with 2 × 10⁶ purified and CFSE-labeled T cells from WT B6 mice. Recipient mice were injected IV with scrambled, anti-miR-17, or anti-miR-19 at 25 mg/kg on day 0 and 5 mg/kg on day 2. Recipients were killed on day 4 after cell transfer, and splenocytes were counted and stained for surface expression of H2K^b (donor marker), CD4, CD8 on gated live cells (A), and intracellular IFNγ along with CFSE profile gated on H2K^b+ CD4⁺ or CD8⁺ cells (C). Absolute numbers of CD4⁺ or CD8⁺ donor T cells (B), and CFSE-diluted IFN-γ⁺ cells (D) were shown. Four mice were used in each group. In a separate experiment, BALB/c mice were lethally irradiated and transplanted with 5 × 10⁶ TCD-BM alone or with T cells from B6 mice at 1 × 10⁶/mouse. Recipient mice were treated with individual antagomirs as indicated twice per week from 25 mg/kg on day 0 and then 5 mg/kg until day 21 after BMT. Recipient survival (E) was shown on 6 mice per group. Using the same BMT model, recipient mice were also infused with 5000 luciferase-transduced A20 cells at the day of BMT, and treated with individual antagomirs as indicated. Recipient survival (F) and mortality caused by tumor relapse (G) were shown on 4 to 7 mice per group. *P < .05, **P < .01, ***P < .001.